

Figure S4 – Elevated CD9 and Flotillin-1 in a *GRN* Mutation Carrier Who Subsequently Developed MCI.

The plasma EV pellet from a clinically normal *GRN* mutation carrier who went on to develop amnestic MCI (Table 2, case 23, circled in red above) had the highest levels of CD9 (**a**) and flotillin-1 (**b**) among the presymptomatic *GRN* carriers in this study. Data are reproduced from Fig. 5e and f with symptomatic *GRN* patients excluded to better visualize the distribution of controls and presymptomatic *GRN* carriers.